Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

References

• Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114:3139–3146.
   PubMed Web of Science ®Google Scholar
• van de Velde HJ, Liu X, Chen G, . Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92:1399–1406.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, . Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001;27:1037–1043.
   PubMed Web of Science ®Google Scholar
• Blade J, Esteve J, Rives S, . High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000;26:845–849.
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, . Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006;37:731–737.
   PubMed Web of Science ®Google Scholar
• Wang M, Delasalle K, Thomas S, . Complete remission represents the major surrogate marker of long survival in multiple myeloma. Blood 2006;108(Suppl. 1): Abstract 403.
   Google Scholar
• Cavo M, Tosi P, Zamagni E, . Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434–2441.
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Weber D, Dimopoulos M, . Relapsed/refractory multiple myeloma patients treated with lenalidomide/dexamethasone who achieve a complete or near complete response have longer overall survival and time to progression compared with patients achieving a partial response. Blood 2007;110(Suppl. 1): Abstract 3598.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Richardson PG, Rajkumar SV, . The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol 2008;143: 46–53.
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, . Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115–1123.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, . Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93:431–438.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Bolejack V, Hollmig K, . High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827–832.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Zhang L, Katzmann JA, . Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908–4915.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Merlini G, . International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23: 215–224.
   PubMed Web of Science ®Google Scholar
• Morice WG, Hanson CA, Kumar S, . Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007;21:2043–2046.
   PubMed Web of Science ®Google Scholar
• de Tute RM, Jack AS, Child JA, . A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007;21:2046–2049.
   PubMed Web of Science ®Google Scholar
• Mason KD, Juneja S. Go with the flow for monitoring response in myeloma with minimal residual disease. Leuk Lymphoma 2008;49:177–178.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gertz MA, Lust JA, . Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 1996;88:1780–1787.
   PubMed Web of Science ®Google Scholar
• Dingli D, Nowakowski GS, Dispenzieri A, . Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 2006;107:3384–3388.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Witzig TE, Dingli D, . Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005;106: 2276–2279.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Witzig TE, Schroeder G, . Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003;101:827–830.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kyle RA, . Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005;23:5668–5674.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Owen RG, Davies FE, . Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997;97:46–55.
   PubMed Web of Science ®Google Scholar
• Rawstron AC. Immunophenotyping of plasma cells. Curr Protoc Cytom 2006;Chapter 6:Unit6.23.
   PubMedGoogle Scholar
• Manzanera GM, San Miguel Izquierdo JF, Matos AO. Immunophenotyping of plasma cells in multiple myeloma. Methods Mol Med 2005;113:5–24.
   PubMedGoogle Scholar
• Lin P, Owens R, Tricot G, . Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121:482–488.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 2004;32:293–301.
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, . High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999;107:121–131.
   PubMed Web of Science ®Google Scholar
• Subira D, Castanon S, Aceituno E, . Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol 2002;117:952–958.
   PubMed Web of Science ®Google Scholar
• Peceliunas V, Janiulioniene A, Matuzeviciene R, . Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom 2011 Apr 6. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Witzig TE, Kimlinger TK, Ahmann GJ, . Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry 1996;26:113–120.
   PubMedGoogle Scholar
• Witzig TE, Kyle RA, O'Fallon WM, . Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994;87:266–272.
   PubMed Web of Science ®Google Scholar
• Kumar S, Witzig TE, Greipp PR, . Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. Br J Haematol 2003;122:272–274.
   PubMed Web of Science ®Google Scholar